The market shows a low probability for FDA approval of an HIV vaccine by 2027.
Current market sentiment indicates an 84.6% likelihood that an HIV vaccine will not be approved by the FDA by 2027. The Pulse AI suggests a slightly higher probability of 20.9% for approval, but overall confidence remains moderate at 55/100, reflecting uncertainty in the data.